Stockysis — AI-Powered Stock News & Sentiment Analysis

Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target

Benzinga Newsdesk www.benzinga.com Positive 69.3%

Neg 0% Neu 0% Pos 69.3%

Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutral to Overweight and announces $16 price target.

Comments

No comments yet. Be the first!